Madrid-based PharmaMar has submitted the protocol for a Phase 2 trial to the Spanish Medicines and Healthcare Products Agency (AEMPS) to test its multiple myeloma therapy Aplidin (plitidepsin) in people with COVID-19 pneumonia. The trial, named APLICOV, aims to recruit 160 patients across multiple sites in Spain and assess if Aplidin reduces the proportion of...Continue Reading